xIPOmeter
BenevolentAI
BenevolentAI utilizes AI technologies for medicine discovery. The firm has over 20 various drug studies in the pipeline. HQ - London.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
News related to BenevolentAI30
BenevolentAIBenevolentAI announces 3-year collaboration expansion with ...
The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify ...
https://www.streetinsider.com/Press+Releases/BenevolentAI+announces+3-year+collaboration+expansion+with+AstraZeneca+focused+on+systemic+lupus+erythematosus+and+heart+failure/19455518.htmlBenevolentAIPharmaceutical AI Platform and Software Global Market Insights ...
BenevolentAI. Atomwise. AI Therapeutics. Insilico Medicine. Recursion Pharmaceuticals. Lantern Pharma. Adaptive Biotechnologies....
https://uk.finance.yahoo.com/news/pharmaceutical-ai-platform-software-global-132100228.htmlBenevolentAIValneva: Chikungunya vaccine trial met primary endpoint after ...
Chikungunya is a viral disease transmitted to humans by infected mosquitoes and there is currently no vaccine or specific drug against the virus....
https://www.nasdaq.com/articles/valneva%3A-chikungunya-vaccine-trial-met-primary-endpoint-after-positive-phase-3-resultsBenevolentAIValneva says Chikungunya vaccine Phase 3 trial has met primary ...
Chikungunya is a viral disease transmitted to humans by infected mosquitoes that causes fever as well as muscle and joint pain....
https://www.nasdaq.com/articles/valneva-says-chikungunya-vaccine-phase-3-trial-has-met-primary-endpointBenevolentAIData hunters will be Big Pharma's next prey | Nasdaq
BenevolentAI uses artificial intelligence to accelerate drug discovery. - Drugmakers globally spend $160 billion on new research and development each year, ...
https://www.nasdaq.com/articles/data-hunters-will-be-big-pharmas-next-prey
Show more (25)Investors6
Goldman Sachs
Woodford Investment Management
Lundbeck
Upsher Smith Laboratories
Lansdowne Partners
Temasek Holdings